Launch Week 14 · Focus: Speed to therapy, access and persistence
Framework v1.2 for this phase
+5
47
Active patients on commercial ulefnersen
29 new starts · 18 transitioned from EAP/trials · vs W13
Certified KPI
+2
4
New starts this week
Plan 4 · vs W13
Certified KPI
0
Not yet evaluable
Month-6 persistence
First month-6 cohort matures around W26 · vs W13
Certified KPI
+2pt
82%
Treatment-decision completion (30 days)
41 of 50 evaluated qualifying patients · vs W13
Certified KPI
0pt
8%
Final denial rate
3 of 40 final decisions · vs W13
Certified KPI
+2pt
92%
Sales attainment (% of forecast)
National · 21 ordering sites · vs W13
Certified KPI
Patient Pathway Funnel
Stages 2–6 · cumulative patients · Launch Week 14
Stage 1 · HCP engagement
63%
Priority-account pathway adoption
19 of 30 priority accounts · account measure, not patients
Stage 4 · Treatment readiness
77%
Treatment-center readiness
20 of 26 centers meet all 4 requirements · account measure, not patients
73% conversionmedian 9d
81% conversionmedian 6d
88% conversionmedian 4d
93% conversionmedian 7d
86% conversionmedian 11d
84% conversionmedian 11d
94% conversion
New-start cohort only; transitions are additional. See Patient bridge.
Performance Brief – Week 14
Initial illustrative brief · Sample review status
Claims feed 3 days late – claims-derived numbers held at W13.
What changed
- 4 new commercial starts this week brought active commercial patients to 47 (29 new starts, 18 transitioned from EAP/trials). KPI: New starts · Hub · W14KPI: Total active commercial patients · SD 867 · W14
- Median time to coverage rose from 15 to 18 days, driven by 3 Medicaid cases in the Southeast awaiting genetic report re-submission. KPI: Time to coverage · Hub · W14KPI: Denial reasons · Hub · W14
- EAP/trial transition reached 82% (18 of 22); 3 in progress and 1 gap in therapy. Transitioned patients are included in total active commercial, not in the new-start funnel. KPI: EAP transition · EAP registry · W14
Why it matters
- Referral-to-first-dose is 33 days vs a 30-day target; coverage is the largest single contributor (18 of 33 days). KPI: Referral → first dose · Hub + SD · W14
- Month-6 persistence is not yet evaluable; the first month-6 cohort matures around W26. Interim: 29 of 31 new starts remain active since first dose. KPI: Month-6 persistence · SD 867 + Hub · W14
- Sales attainment is 92% of forecast nationally (Northeast 104%, South Central 81%). KPI: Sales attainment · Internal sales · W14
What to watch
- 6 patients stalled at benefits verification → coverage; 4 exceed the 14-day threshold, concentrated in Southeast Medicaid. KPI: Stalled patients · Hub · W14
- Claims feed is 3 days late; claims-derived figures are held at Week 13 until arrival. DQ: Claims freshness · W14
Patient bridge
Total active commercial: 47 · 29 new starts · 18 transitioned from EAP/trials
Certified KPI
3 transitions in progress · 1 gap in therapy (alert)
Sales attainment vs forecast by region
% of forecast only · no currency values · National 92%
Dashed line = 100% of forecast. Source: internal sales + SD 867 · Launch Week 14.
Weekly new starts vs plan
First commercial doses · W1–W14
Active new-start patients
Excludes EAP/trial transitions · vs cumulative new-start plan